t
On 6 October 2023, ValiRx PLC noted a recent increase in its share price and confirmed it holds no unpublished price-sensitive information. The company also noted an announcement by EUDA Health Holdings Limited regarding its proposed merger with TheoremRx Inc. ValiRx's clinical asset VAL201 remains subject to a Letter of Intent with TheoremRx Inc., which was initially announced on 2 November 2021.
| Date | 6 Oct 2023 |
| Time | 10:45:59 |
| Category | Corporate updates |
| ID | 9971O |
6 October 2023
ValiRx PLC ("ValiRx" or the "Company")
Statement re Share Price Movement
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, notes the recent increase in the Company's share price and confirms that it is not in possession of unpublished price sensitive information.
The Company notes the announcement published by EUDA Health Holdings Limited in relation to its proposed merger with TheoremRx Inc. The announcement can be viewed in full at the link below:
As initially announced on 2 November 2021, VAL201, the Company's clinical asset for prostate cancer, remains subject to the Letter of Intent with TheoremRx Inc.
The Directors of the Company take responsibility for this announcement.
*** ENDS ***
For more information, please contact:
|
ValiRx plc
Dr Suzanne Dilly, CEO
|
Tel: +44 (0) 2476 796496
|
|
V Formation (Public Relations)
Lucy Wharton - Senior PR Executive Sue Carr - Director
|
+44 (0) 115 787 0206
|
|
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray/ Ludovico Lazzaretti
|
Tel: +44 (0) 20 7213 0880 |
|
Cavendish Securities plc (Joint Broker)
Dale Bellis/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate Finance) |
Tel: +44 (0) 20 7397 8900 |
|
Turner Pope Investments (Joint Broker) James Pope / Andy Thacker |
Tel: +44 (0) 20 3657 0050
|
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com